Overview
Hongyue Li practices practicing medicine in Kashgar, China.
Their clinical expertise encompasses Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Hodgkin Lymphoma, and Interstitial Cystitis.
They are actively involved in clinical research, co-authoring 8 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Hongyue Li
Is Hongyue Li a top-rated expert for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)?
MediFind is an objective health platform that identifies experts based on real-world data. Hongyue Li is classified as an Experienced expert for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Hongyue Li participate in research or clinical trials?
Yes. Hongyue Li has published 8 articles and abstracts on conditions like Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). You can view a list of Hongyue Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Hodgkin LymphomaLi isExperienced. Learn about Hodgkin Lymphoma.
- Interstitial CystitisLi isExperienced. Learn about Interstitial Cystitis.
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)